<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590187</url>
  </required_header>
  <id_info>
    <org_study_id>CYC682-06</org_study_id>
    <nct_id>NCT00590187</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients</brief_title>
  <official_title>A Randomized Phase 2 Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cyclacel Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cyclacel Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to learn which sapacitabine treatment is more likely to
      keep the cancer in check for at least one year in AML patients who are at least 70 years of
      age or older and in MDS patients who are at least 60 years of age.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2007</start_date>
  <completion_date type="Actual">December 1, 2018</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate and duration of complete remission and complete remission without blood count recovery, transfusion requirements, hospitalized days and safety</measure>
    <time_frame>during study</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">408</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>A sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg b.i.d. x 7 days every 3-4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg b.i.d. x 7 days every 3 - 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg b.i.d. x 7 consecutive days every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>E sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg q.d. x 7 consecutive days every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg b.i.d. x 7 consecutive days every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>H sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg q.d. x 7 consecutive days every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>I sapacitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>200 mg b.i.d. x 7 days every 3-4 weeks</description>
    <arm_group_label>A sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>300 mg b.i.d. x 7 days every 3 - 4 weeks</description>
    <arm_group_label>B sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks</description>
    <arm_group_label>C sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>200 mg b.i.d. x 7 consecutive days every 4 weeks</description>
    <arm_group_label>D sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>300 mg q.d. x 7 consecutive days every 4 weeks</description>
    <arm_group_label>E sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks</description>
    <arm_group_label>F sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>200 mg b.i.d. x 7 consecutive days every 4 weeks</description>
    <arm_group_label>G sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>300 mg q.d. x 7 consecutive days every 4 weeks</description>
    <arm_group_label>H sapacitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sapacitabine</intervention_name>
    <description>100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks</description>
    <arm_group_label>I sapacitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A histologically or pathologically confirmed diagnosis of AML based on WHO
             classification which is previously untreated by systemic therapy or is in first
             relapse after achieving a complete remission to initial induction, consolidation
             and/or maintenance therapy or MDS with IPSS scores of intermediate -2 or higher risk
             risk which has been previously treated with hypomethylating agents

          -  Age 70 years or older for AML and 60 years or older for MDS

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Adequate renal function defined as serum creatinine equal to or less than 1.5 x upper
             limit of normal (ULN)

          -  Adequate liver function defined as total bilirubin or direct bilirubin equal to or
             less than 1.5 x ULN; alanine aminotransferase (ALT or SGPT) equal to or less than 2.5
             x ULN (5 x ULN if tumor has affected the liver)

          -  Life expectancy reasonably adequate for evaluating the treatment effect

          -  Patient must be able to swallow capsules

          -  Patients must be at least 2 weeks from prior systemic therapy, radiation therapy,
             major surgery, or other investigational therapy, and have recovered from clinically
             significant toxicities of these prior treatments

          -  All men and women of reproductive potential must agree to practice effective
             contraception for 4 weeks prior to study entry, during the entire study period and for
             one month after the study unless documentation of infertility exists

          -  Ability to understand and willingness to sign the informed consent form

        Exclusion Criteria:

          -  AML is of the sub-type of acute promyelocytic leukemia

          -  Having received more than one induction systemic therapy for AML or having received a
             standard dose or high dose ara-C containing regimen for MDS

          -  Patients with known central nervous system (CNS) involvement by leukemia

          -  Uncontrolled intercurrent illness including, but not limited to ongoing or active
             infection, active cancer(s) other than AML, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements. Patients receiving intravenous
             antibiotics for infections that are under control may be included in this study

          -  Known to be HIV-positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hagop M Kantarjian, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Division of Hematology-Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Cancer Research Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68198</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institiute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Medical College</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <zip>10532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Penn State Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt U Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70436-9/fulltext</url>
    <description>Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study.</description>
  </link>
  <results_reference>
    <citation>Kantarjian H, Faderl S, Garcia-Manero G, Luger S, Venugopal P, Maness L, Wetzler M, Coutre S, Stock W, Claxton D, Goldberg SL, Arellano M, Strickland SA, Seiter K, Schiller G, Jabbour E, Chiao J, Plunkett W. Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study. Lancet Oncol. 2012 Nov;13(11):1096-104. doi: 10.1016/S1470-2045(12)70436-9. Epub 2012 Oct 15.</citation>
    <PMID>23075701</PMID>
  </results_reference>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>December 23, 2007</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2008</study_first_posted>
  <last_update_submitted>January 23, 2019</last_update_submitted>
  <last_update_submitted_qc>January 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sapacitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

